Merck (MRK) Stock
NASDAQ · MRK
146.87
Fundamentals
Market cap
$362.35B
Price / Earnings ratio
114.4x
Price / Sales ratio
5.5x
Price / Book ratio
8.7x
Return on assets
0.1%
Ex-Dividend date
15 Sep 2026
Last payment date
N/A
Dividend amount
$0.85
Dividend yield
2.3%
Debt / Equity ratio
N/A
Latest news
About Merck
For more than 125 years, Merck (known as MSD outside of the U.S. and Canada) has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives.
SectorHealthcare
IndustryDrug Manufacturers - General
Employees73,000
CEOMr. Robert M. Davis J.D.
IPO DateJan 13, 1978
HeadquartersRahway, NJ
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert M. Davis J.D. | Chairman, President & CEO | 1967 |
| Ms. Caroline A. Litchfield | Executive VP & CFO | 1969 |
| Ms. Jennifer L. Zachary J.D. | Executive VP & General Counsel | 1978 |
| Dr. Dean Y. Li M.D., Ph.D. | Executive VP & President of Merck Research Laboratories | 1963 |
| Mr. Dalton E. Smart III | Senior VP of Finance, Principal Accounting Officer & Global Controller | 1967 |
| Mr. David Michael Williams | Executive VP and Chief Information & Digital Officer | 1969 |
| Mr. Peter Dannenbaum | Vice President of Investor Relations | — |
| Mr. Chirfi Guindo | Executive Vice President of Strategic Access, Policy & Communications | 1966 |
| Ms. Betty D. Larson | Executive VP & Chief Human Resources Officer | 1976 |
| Mr. Richard R. DeLuca Jr. | Executive VP & President of Merck Animal Health | 1963 |
Fundamentals
Valuation
Market cap$362.35B
Price-to-sales ratio5.45
Price-to-book value8.66
Price-earnings ratio114.40
Return on Equity18.00%
Return on Sales0.20%
Return on Assets0.07%
PEG ratio2.69
Earnings Per Share
Earnings Per Share$1.27
Income Statement
Average volume10,926,175
EBITDA$19.40B
1 year high (52w)$156.92
1 year low (52w)$77.58
Dividend
Ex dividend date15 Sep 2026
Dividend amount$0.85
Dividend yield2.31%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



